Reaching Schizophrenia Lead Clinicians
Fifteen interviews with regional lead psychiatrists revealed how schizophrenia care shifts across settings and how best to reach the clinicians who shape it.
A pharmaceutical company wanted to understand how UK psychiatrists treat the positive and negative symptoms of schizophrenia, how they trial new drugs, and which channels reach them best.
Rather than a broad sample, the recruit focused on seniority and setting. Most respondents were lead clinicians for schizophrenia in their region. Together, they covered the main settings a patient may pass through:
Early intervention services
Forensic psychiatry, including the main prescriber in a high-secure unit
Community mental health
Acute inpatient and crisis care
Respondents were from across England and Wales, with 14 to 30 years' experience as psychiatrists. Several were responsible for around 200 patients each. Each took part in a 45-minute interview.
Covering different settings mattered because patients move between them, and many psychiatrists do too. Interviews showed priorities shift along the way: positive symptoms and patient insight often come first, while negative symptoms can become more visible once patients are back in the community.
The channel findings were practical. Psychiatrists reported reading core journals online and attending specialist congresses, while none reported using dedicated professional social platforms. A minority no longer see sales reps at all.
A small, senior sample gave the client a clear view of how to approach different prescriber groups.
